MARKET

ICPT

ICPT

Intercept Pharmaceuticals Inc
NASDAQ
14.56
-0.21
-1.42%
After Hours: 14.56 0 0.00% 16:01 11/28 EST
OPEN
14.82
PREV CLOSE
14.77
HIGH
14.92
LOW
14.35
VOLUME
589.46K
TURNOVER
0
52 WEEK HIGH
21.25
52 WEEK LOW
10.81
MARKET CAP
603.03M
P/E (TTM)
-2.3981
1D
5D
1M
3M
1Y
5Y
Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022
MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today anno...
GlobeNewswire · 6d ago
Analyst Ratings for Intercept Pharmaceuticals
Benzinga · 11/16 20:01
HC Wainwright & Co. Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $14
Benzinga · 11/16 19:07
--HC Wainwright Adjusts Intercept Pharmaceuticals Price Target to $14 From $16, Maintains Neutral Rating
--HC Wainwright Adjusts Intercept Pharmaceuticals Price Target to $14 From $16, Maintains Neutral Rating
MT Newswires · 11/16 11:58
Intercept Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Intercept Pharmaceuticals ( NASDAQ:ICPT ) Third Quarter 2022 Results Key Financial Results Revenue: US$77.6m (up 16...
Simply Wall St. · 11/08 12:37
Reported Late Monday, Intercept Announces Development Program For Next-Generation FXR Agonist INT-787 In Severe Alcohol-Associated Hepatitis
Benzinga · 11/08 05:18
Intercept updates Phase 3 data for the NASH candidate
Seekingalpha · 11/07 14:22
Intercept Announces Additional Data In Fibrosis Due To NASH From New Analysis Of Phase 3 REGENERATE Study At AASLD The Liver Meeting 2022
Benzinga · 11/07 13:14
More
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.

Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.